Chengdu Kanghong Pharmaceutical Group
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China.[1] It was founded in 1996 and researches, develops, manufactures, and distributes medicines[2] for ophthalmic, central nervous, digestive and endocrine systems.[1] The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion.[3][4]
As of May 2021, the company had 18 drugs on the market including Lumitin (conbercept).[5] Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona (Mosapride Citrate), Bolexin (Venlafaxine hydrochloride capsules) and Bosiqing (Aripiprazole tablets), Yitaning (Dexzopiclone tablets), Shugan Jieyu (capsules), Danshu (capsules), and Yiqing (capsules).[2][6] Kanghong also currently has 13 subsidiaries in China, Israel, and the United States.[7]
History
[edit]In 2005, Kanghong started development of the drug conbercept, which is used to treat age-related macular degeneration (AMD).[1] In 2017, Kanghong acquired IOPtima, a subsidiary of BioLight Israeli Life Sciences Investment.[4] Kanghong also became a distributor of IOPtima’s products in China.[4]
In 2016, Kanghong received approval from the U.S. FDA to begin Phase III clinical trials of conbercept. In 2020, the company’s R&D investments were approximately 29% of its annual revenue,[8] and by 2020, the company held 238 patents and exclusive patents for 13 drugs out of their 18 products.[5]
As of December 2020, the company’s drugs in development are for treatment of various diseases and conditions including glioma, fundus disease tumors, diabetic macular edema (DME), and Type II diabetes.[9]
During the COVID-19 pandemic, Kanghong donated money, protective clothing, and other materials to medical institutions across China through the China Red Cross Foundation.[10][11]
References
[edit]- ^ a b c "China Focus: Innovation boosts development of China's private medical companies". www.xinhuanet.com. Archived from the original on 2018-12-17. Retrieved 2021-05-27.
- ^ a b "002773.SZ - Chengdu Kanghong Pharma Grp Co Ltd Profile | Reuters". www.reuters.comundefined. Archived from the original on 2021-05-25. Retrieved 2021-05-27.
- ^ Baumer, Lilach (2018-09-27). "Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company". CTECH - www.calcalistech.com. Retrieved 2021-05-27.
- ^ a b c "Chengdu Kanghong Pharma buys Israel's IOPtima for $56m". Globes. 2017-11-21. Retrieved 2021-05-27.
- ^ a b "康弘药业亮相中国品牌日 | 北晚新视觉". www.takefoto.cn. Retrieved 2021-06-16.
- ^ "康弘药业：能成为第二个恒瑞医药吗？ | 风云独立研报". finance.ifeng.com. Retrieved 2021-06-16.
- ^ "成都康弘药业集团股份有限公司_药智新闻". news.yaozh.com. Retrieved 2021-05-27.
- ^ "康弘药业2020年研发投入同比增长21.26% 加快创新布局未来 _ 东方财富网". finance.eastmoney.com. Retrieved 2021-05-27.
- ^ "康弘药业迎难而上，开拓研发创新新版图". finance.ifeng.com. Retrieved 2021-05-27.
- ^ "康弘药业疫情大考中彰显责任与创新-新华网". www.xinhuanet.com. Archived from the original on April 17, 2020. Retrieved 2021-06-16.
- ^ "与"白衣战士""战"在一起 康弘药业又一批国际采购医用防护物资到位". 2020-03-09. Archived from the original on 2021-06-24.